Total regression of hepatocellular carcinoma bone metastases, after liver transplantation, with sorafenib-everolimus

作     者：Dimitrios Giakoustidis Athanasios Apostolos Gargavanis Nikolaos Salveridis Evangelos Cholongitas Emmanouil Sinakos Konstantinos Papapolychroniadis Vassilios Papanikolaou 

作者机构：Division of Transplant SurgeryDepartment of SurgeryMedical SchoolAristotle University of ThessalonikiHippokration General Hospital54642hessalonikiGreece The4th Department of Internal MedicineMedical SchoolAristotle University of ThessalonikiHippokration General Hospital54642ThessalonikiGreece 

出 版 物：《Hepatoma Research》 (肝癌研究（英文版）)

年 卷 期：2017年第3卷第9期

页      面：205-208页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Liver transplantation hepatocellular carcinoma bone metastases sorafenib everolimus 

摘      要：Hepatocellular carcinoma (HCC) represents the 5th commonest malignancy worldwide. Liver transplantation consist a radical and most efficient treatment for HCC. Tumor recurrence or metastases after liver transplantation is not uncommon. Hereby is presented a case of a patient transplanted for alcoholic liver disease and HCC and presented with bone metastases a few months later. Treatment with sorafenib and everolimus showed full regression of the metastases. In conclusion, the point of this report is to advertise a single case of total regression of bone lesions due to HCC recurrence, with the combination of mammalian target of rapamycin and sorafenib, along with radiation.